Myriad Genetics Inc
MYGN
NASDAQ
Biotechnology
$3.03
USD
-0.14 (-4.42%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $307.03M
Volume 1.6M
Revenue
$806.60M
TTM
-3.2%
YoY
Gross Margin
69%
TTM
-2.3%
YoY
Net Income
$-112.60M
TTM
+71.5%
YoY
Operating Cash Flow
$7.70M
TTM
+134.1%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 213.1 | 205.7 | 209.8 | 200.4 | 190.7 |
YoY Growth | +0.8% | -3.6% | -0.4% | +2.3% | -10.5% |
Cost of Revenue | 61.3 | 61.9 | 63.0 | 62.8 | 63.7 |
Gross Profit | 151.8 | 143.8 | 146.8 | 137.6 | 127.0 |
Selling, General & Administrative | 138.7 | 138.9 | 124.3 | 135.8 | 140.9 |
Other Operating Expenses | 316.7 | 0.0 | 2.7 | 5.4 | 0.0 |
Total Operating Expenses | 481.0 | 167.1 | 152.5 | 168.3 | 165.9 |
Operating Income | -329.2 | -23.3 | -5.7 | -30.7 | -38.9 |
EBITDA | 1.6 | -10.7 | 9.6 | -12.8 | -26.4 |
Other Income / Expense | -0.1 | 0.4 | 0.4 | 0.0 | 0.0 |
Total Other Income / Expense | -1.4 | -2.9 | -3.2 | -3.4 | -3.7 |
Income Before Income Taxes | -330.6 | -26.2 | -8.9 | -34.1 | -42.6 |
Income Taxes | -0.1 | 1.2 | -1.0 | 0.0 | 0.6 |
Net Income | -330.5 | -27.4 | -7.9 | -34.1 | -43.2 |
Consolidated Net Income / Loss | -330.5 | -27.4 | -7.9 | -34.1 | -43.2 |
Net Income Attributable to Common Shareholders | -330.5 | -27.4 | -7.9 | -34.1 | -43.2 |
Basic EPS | -$3.57 | -$0.29 | -$0.08 | -$0.36 | -$0.46 |
Diluted EPS | -$3.57 | -$0.29 | -$0.08 | -$0.36 | -$0.46 |
Basic Shares Outstanding | 92.5M | 93.1M | 93.4M | 93.7M | 94.8M |
Diluted Shares Outstanding | 92.5M | 93.1M | 93.4M | 93.7M | 94.8M |